The growing emergence of biotech companies and specialized knowledge base has lead to a shift in strategic focus for life science companies. Even though R&D spend is on the rise, companies still look to external targets as a means of supplementing pipelines and bolstering their product portfolios. The need to expand the reach of R&D programs has driven major new investments in co-development, licensing, acquisitions and strategic alliances, as companies look to gain access to new sources of innovation.
With so many factors affecting the potential value of a transaction, it is essential for life science organizations to effectively assess the risks associated with a deal, explore innovative models and deal structures for working with strategic partners, collaborate with cross-functional partners to realize business synergies, and develop processes for the efficient and optimal negotiation and closing of a transaction.
The
BD&L Summit for Life Sciences will provide attendees with valuable insights and actionable strategies from cross-functional business development teams in successfully managing alliances, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and will feature leadership representation from biotechs, mid-sized and large pharmaceutical, medical device and diagnostics companies.
Who Should Attend:
This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
- Business Development
- Mergers and Acquisitions
- Licensing
- Strategic Alliance/Alliance Management
- Intellectual Property and Patent Counsel
- Search and Evaluation
- Due Diligence
- External Innovation
- Transactions
- Portfolio Management
- Scientific Assessment
- General Counsel/Corporate Counsel
- Legal and Regulatory Compliance
- Regulatory Affairs
- Research and Development
- Clinical Medicine
- Clinical Operations
- Lifecycle Management
This conference is also of interest to:
- Investment Banks
- Private Equity Firms
- Venture Capitalists
- Data Room Providers
- Due Diligence Consultants
- Law Firms
- Clinical Affairs and CRO Partners
- Regulatory Affairs and Compliance Partners
Speakers
- Brian Axe, Due Diligence Leader, ELANCO
- Matthew Batters, J.D., Executive Director, Transactions, Alliance Management, Business Development and Corporate Counsel, ARVINAS
- Lisa Beck, Vice President, Business Development and Alliance Management, BRII BIOSCIENCES
- Zubin Bhagwagar, M.D., Ph.D., Global Program Lead, RALLYBIO
- Janice Bourque, Managing Director, Life Sciences, HERCULES CAPITAL
- Isaac J. Bright, Chief Executive Officer, RUBRYC THERAPEUTICS
- Brian Bronk, Ph.D., Head of External Innovation, Rare Diseases, SANOFI
- Sascha Bucher, Head of Global Transactions and Head Basel Office, ROIVANT SCIENCES
- Kleem Chaudhary, Head BD&L MS, AD, OPN, Platforms, BIOGEN
- Philip Datlow, Director and Senior Counsel, Intellectual Property, BOEHRINGER INGELHEIM
- Behrad Derakhshan, Ph.D., Vice President, Head of Business Development, THERACON
- Niels P. Emmerich, Vice President, Global Head Search and Evaluation, ABBVIE
- John Fair, Chief Business Officer, DARE BIOSCIENCE
- Teresa Faria, Senior Director, Alliance Management, External Scientific Affairs, DAIICHI SANKYO
- Steven Gurney, Principal Associate and Patent Attorney, MARKS & CLERK
- Joe Herold, Chief Legal Officer and Chief Compliance Officer, DRI CAPITAL
- Timothy Herpin, Chief Business Officer, CARIBOU BIOSCIENCES
- Ruby Holder, Vice President, Investments, ROIVANT SCIENCES
- Rick Hoyt, Vice President, Business Development and Licensing, MALLINCKRODT
- Will James, Partner and Solicitor, MARKS & CLERK
- Chinmay Kanuga, Director, Scientific Assessments and Due Diligences, ALLERGAN
- Adam Kundzewicz, Ph.D., Head of Strategic Market Access Initiatives, BOEHRINGER INGELHEIM
- Tom Lynch, Chief Administrative Officer, General Counsel and Secretary, OREXIGEN
- Bethany Mancilla, Chief Business Officer and Senior Vice President, CUE BIOPHARMA
- Mike Myers, Senior Director, Lilly Research Labs - Due Diligence, ELI LILLY
- Carolyn Ng, Principal, VERTEX VENTURES HC
- George Ng, President, Business, SCILEX PHARMACEUTICALS
- Tara Nickerson, Chief Business Officer, THIRD ROCK VENTURES
- Mark E. Nuttall, Chief Business Officer, KYMERA THERAPEUTICS
- William Pedranti, President, Operations, SCILEX PHARMACEUTICALS
- Martin Picard, Ph.D., Vice President, Global Head Search, Evaluation and Due Diligence, MERCK KGAA
- Joel Sangerman, Chief Commercial Officer, CLICK THERAPEUTICS
- Marc Schwabish, Senior Vice President, Business Development and U.S. Operations, FUSION PHARMACEUTICALS
- Peter Seufer-Wasserthal, Chief Business Officer, ORIGENIS
- Felice Shieh, Senior Director, External Science and Innovation, PFIZER
- Kristen B. Slaoui, Vice President, Head of Business Development, North America, Corporate Strategy and Development, GSK
- Chris Slavinsky, Assistant General Counsel, PFIZER
- Jackie Spencer, Managing Director, Life Sciences and Healthcare, SILICON VALLEY BANK
- Peter Trybus, Senior Corporate Counsel, Healthcare Law, Managed Care Practice Group, GENENTECH
- Michah Zajic, Vice President, Corporate Development, MEIRAGTX
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Venue
Hyatt Fisherman's Wharf555 North Point Street
San Francisco, CA 94133
